November 20, 2019
  • November 20, 2019
Breaking News
  • Home
  • Business
  • FDA granted Orphan Drug Designation for Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) lead product

FDA granted Orphan Drug Designation for Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) lead product

By on June 28, 2019 0

Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) said the FDA has granted Orphan Drug Designation for its lead product candidate ARCT-810 to treat ornithine transcarbamylase deficiency – the most common urea cycle disorder that makes it difficult for the removal of toxic waster products as proteins are digested. Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT), a Financial sector firm, traded 103384 shares in last trading session with closing price of $9.68 per share. Stock value has moved between $4.1 – 10.3 in last one year. Analyst’s mean target price for Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) is $18.50 while analysts mean recommendation is 1.80. ARCT EPS growth this year is 38.70%.

On last trading day, Maxim Integrated Products, Inc. (NASDAQ:MXIM) shares closed at $60.15 per share. MXIM market capitalization is 16366.82 with beta of 1.38. Analyst’s mean target price for Maxim Integrated Products, Inc. (NASDAQ:MXIM) is $61.78 whereas analysts mean recommendation is 2.80. Its weekly performance is 3.10% while year to date (YTD) performance is 18.29%.

In last session Bristol-Myers Squibb Company (NYSE:BMY) traded 10.91 Million shares and was closed at $45.10. Analyst’s mean target price for BMY is $56.10 while analysts mean recommendation is 2.30. Company is -29.19% away from its 52 week high and is moving 1.81% ahead of its 52 week low. BMY Gross Margin is 71.10% and its return on assets is 15.10%. Bristol-Myers Squibb Company (NYSE:BMY) quarterly performance is -5.73% while its price to sale ratio is 3.16.

Pfizer Inc. (NYSE:PFE), a Healthcare sector firm, traded 20.79 Million shares on last trading day with closing price of $43.43 per share. Company gross margin stands at 79.60% whereas its return on investment (ROI) is 10.20%. Stock value has moved between $35.89 – 46.7 in last one year. Analyst’s mean target price for Pfizer Inc. (NYSE:PFE) is $45.57 while analysts mean recommendation is 2.40. PFE EPS growth this year is -11.90%.



Leave a comment